Case Report: A Highly Active Refractory Myasthenia Gravis with Treatment of Telitacicept Combined with Efgartigimod

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 27

PMID 38799457

Authors

Chaoyue Zhang

Yangtao Lin

Qianjin Kuang

Hongjin Li

Qilong Jiang

Xiaojun Yang

Affiliations

Soon will be listed here.

Abstract

There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.

Citing Articles

Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review.

Zhang J, Hu M, Wang C, Guo S Front Immunol. 2025; 16:1509143.

PMID: 39981240 PMC: 11839722. DOI: 10.3389/fimmu.2025.1509143.

Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod.

Yang M, Yuan J, Wang Y, Hao H, Zhang W, Wang Z Front Immunol. 2024; 15:1447182.

PMID: 39502686 PMC: 11534618. DOI: 10.3389/fimmu.2024.1447182.

Efgartigimod as Rescue Medication in a Patient with Therapy-Refractory Myasthenic Crisis.

Alhaj Omar O, Diel N, Gerner S, Muck A, Huttner H, Kramer-Best H Case Rep Neurol Med. 2024; 2024:9455237.

PMID: 38939234 PMC: 11211016. DOI: 10.1155/2024/9455237.

References

Wiendl H, Abicht A, Chan A, Marina A, Hagenacker T, Hekmat K . Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023; 16:17562864231213240. PMC: 10752078. DOI: 10.1177/17562864231213240. View

Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M . Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023; 94(6):467-473. DOI: 10.1136/jnnp-2022-330519. View

Evoli A, Damato V . Conventional and emerging treatments and controversies in myasthenia gravis. Expert Rev Neurother. 2023; 23(5):445-456. DOI: 10.1080/14737175.2023.2207739. View

Smith M . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22(47):7359-68. DOI: 10.1038/sj.onc.1206939. View

Mantegazza R, Antozzi C . When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018; 11:1756285617749134. PMC: 5791553. DOI: 10.1177/1756285617749134. View

Mahmoud S, Buhler J, Chu E, Chen S, Human T . Drug Dosing in Patients Undergoing Therapeutic Plasma Exchange. Neurocrit Care. 2020; 34(1):301-311. DOI: 10.1007/s12028-020-00989-1. View

Lascano A, Lalive P . Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2020; 20(1):102712. DOI: 10.1016/j.autrev.2020.102712. View

Tandan R, Hehir 2nd M, Waheed W, Howard D . Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017; 56(2):185-196. DOI: 10.1002/mus.25597. View

Howard Jr J, Bril V, Vu T, Karam C, Peric S, Margania T . Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021; 20(7):526-536. DOI: 10.1016/S1474-4422(21)00159-9. View

10.

Cornelis R, Chang H, Radbruch A . Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells. Curr Opin Immunol. 2021; 71:97-102. DOI: 10.1016/j.coi.2021.06.012. View

11.

Punga A, Maddison P, Heckmann J, Guptill J, Evoli A . Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022; 21(2):176-188. DOI: 10.1016/S1474-4422(21)00297-0. View

12.

Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W . Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016; 82(1):41-52. PMC: 4917793. DOI: 10.1111/bcp.12908. View

13.

Yao X, Ren Y, Zhao Q, Chen X, Jiang J, Liu D . Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021; 159:105704. DOI: 10.1016/j.ejps.2021.105704. View

14.

Hewett K, Sanders D, Grove R, Broderick C, Rudo T, Bassiri A . Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018; 90(16):e1425-e1434. PMC: 5902787. DOI: 10.1212/WNL.0000000000005323. View

15.

Watanabe K, Ohashi S, Watanabe T, Kakinuma Y, Kinno R . Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol. 2024; 15:1321058. PMC: 10838969. DOI: 10.3389/fneur.2024.1321058. View

16.

Beecher G, Putko B, Wagner A, Siddiqi Z . Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Drugs. 2019; 79(4):353-364. DOI: 10.1007/s40265-019-1065-0. View

17.

Schweighoffer E, Tybulewicz V . BAFF signaling in health and disease. Curr Opin Immunol. 2021; 71:124-131. DOI: 10.1016/j.coi.2021.06.014. View

18.

Fichtner M, Hoehn K, Ford E, Mane-Damas M, Oh S, Waters P . Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathol Commun. 2022; 10(1):154. PMC: 9617453. DOI: 10.1186/s40478-022-01454-0. View

19.

Dalakas M . Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2018; 15(2):113-124. DOI: 10.1038/s41582-018-0110-z. View

20.

Huijbers M, Marx A, Plomp J, Le Panse R, Phillips W . Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022; 21(2):163-175. DOI: 10.1016/S1474-4422(21)00357-4. View